TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
- 20 December 2021
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 161, 99-107
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated MelanomaNew England Journal of Medicine, 2014
- TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous MelanomaJNCI: Journal of the National Cancer Institute, 2014
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyThe Lancet Oncology, 2014
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsCancer, 2014
- Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future ProspectsJNCI: Journal of the National Cancer Institute, 2014
- Highly Recurrent TERT Promoter Mutations in Human MelanomaScience, 2013
- Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical useJournal of Translational Medicine, 2012
- BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor sitePigment Cell & Melanoma Research, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007